Trending at Lumira Ventures

Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020

admin Forbius, Portfolio News

Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …

Aurinia Partners with National Kidney Foundation on Awareness Initiative

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community …